![Mark Payton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Payton
Chief Executive Officer at
MERCIA ASSET MANAGEMENT PLC
Net worth: 3 M $ as of 2026-07-30
Profile
Mark Andrew Payton is the founder of Mercia Fund Management Ltd., founded in 2009, where the title held is Chief Executive Officer.
Dr. Payton was the founder of Mablyte Ltd., founded in 2013, with the title of Non-Executive Director.
Current jobs include Chief Executive Officer & Executive Director at Mercia Asset Management Plc since 2014, CEO at Mercia Ventures, Chairman at nanoTherics Ltd. since 2013, Director at Enterprise Ventures Group Ltd., Director at Tozaro Ltd., and Director at Mercia Investments Ltd. since 2014.
Former jobs include Director at Hybrid BioSystems Ltd., Director at Abzena (UK) Ltd., Non-Executive Director at Akamis Bio Ltd., Non-Executive Director at The Native Antigen Co., Ltd., Director at Oxford Genetics Ltd., Director at Abzena Ltd. in 2014, Principal at the University of Oxford, Vice President-Corporate Development at Oxxon Therapeutics, Inc. from 2001 to 2005, Portfolio Manager at West Midlands Enterprise Ltd. from 2009 to 2011, Project Manager at Oxford University Innovation Ltd. from 2000 to 2001, and Fund Principal at Wm Enterprise Ltd. from 2005 to 2010.
Education includes an MBA from Warwick Business School, a doctorate from the University of Oxford, and a doctorate from Kings Colleges Ltd.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-08-19 | 7,643,165 ( 1.81% ) | 3 M $ | 2026-07-30 |
Mark Payton active positions
| Companies | Position | Start |
|---|---|---|
| MERCIA ASSET MANAGEMENT PLC | Chief Executive Officer | 2014-12-14 |
nanoTherics Ltd.
 nanoTherics Ltd. Medical SpecialtiesHealth Technology Develops and manufactures magnetic nanoparticle-based products | Chairman | - |
MIP Discovery Ltd. (United Kingdom)
 MIP Discovery Ltd. (United Kingdom) BiotechnologyHealth Technology Develops and manufactures viral vectors in cell & gene therapy | Director/Board Member | - |
Mercia Investments Ltd.
 Mercia Investments Ltd. Financial ConglomeratesFinance Provides investment services | Director/Board Member | 2014-06-29 |
Enterprise Ventures Group Ltd.
 Enterprise Ventures Group Ltd. Investment ManagersFinance Provides venture capital and loans to small businesses | Director/Board Member | - |
Mercia Fund Management Ltd.
 Mercia Fund Management Ltd. Investment ManagersFinance Mercia Fund invests in companies located in the United Kingdom. The firm targets companies operating in a broad range of sectors. It provides financing for seed, early and growth stage capital requirements. The firm also participates in MBOs, buy-in, acquisition financing, debt, and mezzanine transactions with an investment size of GBP 1 - 10 million. It also acquires minority investments. | Chief Executive Officer | 2014-11-30 |
Former positions of Mark Payton
| Companies | Position | End |
|---|---|---|
| ABZENA PLC | Director/Board Member | 2014-06-30 |
West Midlands Enterprise Ltd.
 West Midlands Enterprise Ltd. Miscellaneous Commercial ServicesCommercial Services Alternative investment manager | Private Equity Investor | 2011-02-28 |
Hybrid BioSystems Ltd.
 Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Develops gene therapy treatments for ovarian and prostate cancer | Director/Board Member | 2010-12-14 |
| ░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Mark Payton
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
75
1st degree connections
20
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 20 |
|---|---|
Warwick Business School
 Warwick Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oxxon Therapeutics, Inc.
 Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures antigen-specific immunotherapy’s to treat patients | Health Technology |
West Midlands Enterprise Ltd.
West Midlands Enterprise Ltd. Miscellaneous Commercial ServicesCommercial Services Alternative investment manager | Commercial Services |
Oxford University Innovation Ltd.
 Oxford University Innovation Ltd. Investment ManagersFinance Oxford University Innovation invests in spun out companies located in the United Kingdom. The firm targets companies operating in the fields of across a broad range of sectors and industries. It provides financing for seed and early-stage capital requirements. | Finance |
Hybrid BioSystems Ltd.
Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Develops gene therapy treatments for ovarian and prostate cancer | Commercial Services |
Mercia Fund Management Ltd.
Mercia Fund Management Ltd. Investment ManagersFinance Mercia Fund invests in companies located in the United Kingdom. The firm targets companies operating in a broad range of sectors. It provides financing for seed, early and growth stage capital requirements. The firm also participates in MBOs, buy-in, acquisition financing, debt, and mezzanine transactions with an investment size of GBP 1 - 10 million. It also acquires minority investments. | Finance |
nanoTherics Ltd.
nanoTherics Ltd. Medical SpecialtiesHealth Technology Develops and manufactures magnetic nanoparticle-based products | Health Technology |
PolyTherics Ltd.
 PolyTherics Ltd. Pharmaceuticals: MajorHealth Technology Develops biomedical polymers for therapeutic applications | Health Technology |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that engages in development of tumor gene therapies | Health Technology |
The Native Antigen Co. Ltd.
 The Native Antigen Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Develops viral vectors technologies | Commercial Services |
Enterprise Ventures Group Ltd.
Enterprise Ventures Group Ltd. Investment ManagersFinance Provides venture capital and loans to small businesses | Finance |
Oxford Genetics Ltd.
 Oxford Genetics Ltd. BiotechnologyHealth Technology Develops cell and gene therapies | Health Technology |
Mablyte Ltd.
 Mablyte Ltd. Medical SpecialtiesHealth Technology Develops test kits and reagents to enable the pharmaceutical industries | Health Technology |
Abzena Ltd.
 Abzena Ltd. BiotechnologyHealth Technology Engages in discovery, development and manufactures biologics drugs | Health Technology |
Mercia Asset Management Plc
 Mercia Asset Management Plc Financial ConglomeratesFinance Provides private equity and venture capital fund management services | Finance |
MIP Discovery Ltd. (United Kingdom)
MIP Discovery Ltd. (United Kingdom) BiotechnologyHealth Technology Develops and manufactures viral vectors in cell & gene therapy | Health Technology |
Kings Colleges Ltd.
 Kings Colleges Ltd. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wm Enterprise Ltd. | |
Mercia Investments Ltd.
Mercia Investments Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
- Stock Market
- Insiders
- Mark Payton
